Evidence map›Paper›PMID 24465011›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Jinsong Zhang, S Munir Alam, Hilary Bouton-Verville, Yao Chen, Amanda Newman, Shelley Stewart, Frederick H Jaeger, David C Montefiori, S Moses Dennison, Barton F Haynes and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jinsong ZhangDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710;
S Munir Alam
Hilary Bouton-Verville
Yao Chen
Amanda Newman
Shelley Stewart
Frederick H Jaeger
David C Montefiori
S Moses Dennison
Barton F Haynes
Laurent Verkoczy
Duke University Hospital · USDuke Medical Center · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI BHARDWAJ, NINA · 2006 to 2011
$290.5M
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
MPER broadly neutralizing antibody knockin mice to study anti-HIV Bcell responsesR01AI087202 · NIAID · SAN DIEGO BIOMEDICAL RESEARCH INSTITUTE · PI VERKOCZY, LAURENT KARL · 2010 to 2022
$5.5M
NIAID NIH HHS 5P30-AI064518NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI087202NIAID NIH HHS R01AI087202NIAID NIH HHS U19 AI067854NIAID NIH HHS U19AI067854NIAID NIH HHS UM1 AI100645
6 · The paper itself

Abstract

A goal of HIV-1 vaccine development is to elicit broadly neutralizing Abs (BnAbs), but current immunization strategies fail to induce BnAbs, and for unknown reasons, often induce nonneutralizing Abs instead. To explore potential host genetic contributions controlling Ab responses to the HIV-1 Envelope, we have used congenic strains to identify a critical role for MHC class II restriction in modulating Ab responses to the membrane proximal external region (MPER) of gp41, a key vaccine target. Immunized H-2(d)-congenic strains had more rapid, sustained, and elevated MPER(+) Ab titers than those bearing other haplotypes, regardless of immunogen, adjuvant, or prime or boost regimen used, including formulations designed to provide T cell help. H-2(d)-restricted MPER(+) serum Ab responses depended on CD4 TH interactions with class II (as revealed in immunized intra-H-2(d/b) congenic or CD154(-/-) H-2(d) strains, and by selective abrogation of MPER restimulated, H-2(d)-restricted primed splenocytes by class II-blocking Abs), and failed to neutralize HIV-1 in the TZM-b/l neutralization assay, coinciding with lack of specificity for an aspartate residue in the neutralization core of BnAb 2F5. Unexpectedly, H-2(d)-restricted MPER(+) responses functionally mapped to a core TH epitope partially overlapping the 2F5/z13/4E10 BnAb epitopes as well as nonneutralizing B cell-Ab binding residues. We propose that class II restriction contributes to the general heterogeneity of nonneutralizing gp41 responses induced by Envelope. Moreover, the proximity of TH and B cell epitopes in this restriction may have to be considered in redesigning minimal MPER immunogens aimed at exclusively binding BnAb epitopes and triggering MPER(+) BnAbs.

Indexed as

AIDS VaccinesAnimalsAntibodies, BlockingAntibodies, MonoclonalAntibodies, NeutralizingCD40 LigandCell ProliferationEpitopes, T-LymphocyteHistocompatibility Antigens Class IIHIV AntibodiesHIV Envelope Protein gp41MiceMice, Inbred BALB CMice, Inbred C57BLT-Lymphocytes, Helper-InducerAIDS VaccinesAntibodies, BlockingAntibodies, MonoclonalAntibodies, NeutralizingCD40 LigandEpitopes, T-Lymphocytegp41 protein, Human immunodeficiency virus 1Histocompatibility Antigens Class IIHIV AntibodiesHIV Envelope Protein gp41

Identifiers

PMID24465011
PMCPMC3936991
OpenAlexW2155816055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.